Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Syngenta takeover talk ups pressure for higher returns

Published 24/06/2014, 11:27

ZURICH (Reuters) - Syngenta's (VX:SYNN) shares surged on Tuesday after a media report it had been in merger talks with its largest rival, raising the pressure on the Swiss crop chemicals maker to bolster profits and beef up shareholder returns.

Monsanto Co. (N:MON), the world's largest seed company, and Basel-based Syngenta had held preliminary talks about combining, partly to allow the U.S. company to benefit from lower Swiss holding taxes, according to a report from Bloomberg. The talks were later abandoned.

A Syngenta spokesman declined to comment on the report and Monsanto was not immediately available for comment.

Syngenta shares were 4.6 percent higher at 342.1 Swiss francs(223.61 pounds) in morning trade, the biggest gainers on the pan-European FTSEurofirst 300 index <.FTEU3>.

The reported talks put more pressure on Syngenta Chief Executive Mike Mack to bolster the company's performance and to give money back to shareholders, several analysts including Deutsche Bank and MainFirst said.

"This steadily increasing M&A story plus the activism theme we are seeing in U.S. chemicals mean that management teams in Europe are under more pressure to improve balance sheet efficiency and/or share prices," said Deutsche Bank analyst Virginie Boucher-Ferte. She rates the stock a "buy" with a 400 franc target price.

Syngenta is aiming to increase cost cuts to $1 billion (0.59 billion pounds) a year by 2018 after disappointing investors with an 11 percent fall in 2013 profit. It also aims to boost sales to $25 billion by 2025 from $14.69 billion in 2013.

The tax aspect of Syngenta's potential deal with Monsanto appears to have been similar to drugmaker Pfizer's (N:PFE), failed attempt to buy rival AstraZeneca (L:AZN) for nearly 70 billion pounds.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

That deal would have allowed Pfizer to reincorporate in Britain and pay a significantly lower corporate tax. The U.S. company would also have been able to use tens of billions of dollars it has parked overseas, avoiding high U.S. taxes for repatriating the huge cash pile.

(Reporting by Katharina Bart; Additional reporting by Alice Baghdjian and Rupert Pretterklieber; Editing by Erica Billingham)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.